Thelansis

 Duplication syndrome on chromosome 15q11.2-13.1, also known as Dup15q Syndrome, results from extra genetic material in the 15q11.2-13.1 region, sometimes referred to as the Prader-Willi/Angelman critical region (PWACR). This syndrome is clinically identifiable and is characterized by symptoms such as hypotonia, motor delays, intellectual disability, autism spectrum disorder (ASD), and epilepsy, including infantile spasms. In rare cases, maternal Dup15q may also lead to psychosis or unexplained death. Approximately 30 percent of individuals with Dup15q Syndrome have strabismus (crossed eyes), and about 20-30 percent experience growth-related issues resulting in smaller stature. Hypotonia tends to improve with age, and in some cases, it may progress to hypertonia, especially in the lower legs. Other associated problems include reduced pain sensitivity, scoliosis, recurrent childhood respiratory infections, precocious puberty, menstrual irregularities in females, minor genital abnorm...

 Chromosome 15q11.2-13.1 duplication syndrome (dup15q syndrome) is a clinically identifiable syndrome that results from duplications of the portion of the 15q11.2-13.1 chromosome (also referred to as the Prader-Willi/Angelman critical region (PWACR). ·        The prevalence of dup15q syndrome is unknown. It may be as high as 1 in 5,000 individuals in the general population and is thought to be about ten times more common in people with ASD or intellectual disability. Thelansis’s “Dup15q Syndrome Market Outlook, Epidemiology, Competitive Landscape , and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Dup15q Syndrome treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and Ch...